B&K Corporation Limited (B&K Corp) has enrolled the first patient in its Phase IIIa clinical trial of Pro-101-1, a recombinant human platelet-derived growth factor BB (rhPDGF-BB) gel under development for the treatment of deep second-degree burns.

The randomized, double-blind, placebo-controlled study is designed to assess the efficacy and safety of Pro-101-1 in a large patient cohort and to generate key parameters for the subsequent Phase IIIb trial. Management positions the program as a major research-and-development milestone in the company’s burns-treatment pipeline.

Pro-101-1 is identified by B&K Corp as one of its core assets. The initiation of a Phase IIIa study marks a critical step toward potential commercialization, subject to successful completion of later-stage trials and regulatory approvals.

Pursuant to Rule 18A.05 of the Hong Kong Listing Rules, B&K Corp cautions that it cannot guarantee the ultimate success or market launch of Pro-101-1. Shareholders and potential investors are advised to exercise caution when dealing in the company’s shares.